SAFC: The Age of the Blockbuster Drug has ‘Disappeared’

Sigma-Aldrich Fine Chemicals (SAFC), the fastest-growing division within the Sigma-Aldrich group, says it is adapting its business model to the “significantly” changing business environment. A fundamental change is the shift by big pharmaceutical companies away from blockbuster pharma products toward lower-volume, specialty drugs, says Frank Wicks, president of SAFC. Wicks: More flexibility is required. Pharma companies stand to lose $55 billion in sales during the next five years as a slew of drugs go off patent. “The specter of the blockbuster...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers